Bookmarks
National Cancer TRE
Population Size
Years
2011
Associated BioSamples
None/not available
Geographic coverage
United Kingdom
England
Lead time
2-6 months
Summary
Documentation
NHS Digital’s TRE service for England provides approved researchers with access to essential linked, de-identified health data to quickly answer COVID-19 related research questions. The TRE service provides researchers with support on data access requests, provision of data using the secure data platform the Data Processing Service (DPS) and help with analysis work. Approved research projects will help to guide national decision making and recommend potential interventions to reduce the severity of COVID-19 outcomes. NHSD are delivering the TRE service in partnership with HDRUK. The shared objective is to provide rapid, safe and trustworthy access to data in a transparent way that accelerates the pace of quality research.
Dataset type
Dataset sub-type
Keywords
Provenance
Source of data extraction
Collection source setting
Patient pathway description
Enumerating the impact of COVID-19 on cancer pathways: a robust evaluation of the NHS Digital Trusted Research Environment (TRE).
We will delineate the precise impact of the COVID 19 pandemic on cancer systems and cancer patients. This requires access to both historical data (pre 2020) and near real-time data on patients referred with (i) a suspicion of cancer and (ii) those diagnosed with and/or managed for cancer. Our emphasis is on data on cancer referral
comorbidity and concurrent medication.
We will examine the effects of COVID-19 on: • Cancer referral (including those which lead to a cancer diagnosis and those where cancer is excluded) • Cancer diagnosis (including date
morphology and key molecular/genetic/ phenotype) • Cancer treatment (including surgical procedures
,chemotherapy/targeted therapy and radiotherapy) • Clinical trial activity including recruitment to and active treatment within trials • Outcomes (including both hospital admission
, survival,mortality and cause of death) • COVID status (including COVID testing (Pillar 1&2) and results
,acute hospitalisation and related direct COVID deaths in cancer patients). We will also examine the interaction and impact of other factors including • Age • Ethnicity • Social deprivation (IMD quintile) • Comorbidity (based on both hospital and primary care data) • Concurrent medication (including both hospital and primary care data) • Geography including rurality and health care region • Rates of COVID infection
,hospitalisation and death in discrete health care regions
We will compare activity from 2019 and 2020 but to include patients diagnosed with cancer at any time before then.
Image contrast
Biological sample availability
Structural Metadata
Details
Publishing frequency
Version
Modified
08/10/2024
Distribution release date
01/03/2021
Citation Requirements
Coverage
Start date
01/01/2011
Time lag
Geographic coverage
Maximum age range
Follow-up
10 Years
Accessibility
Language
Controlled vocabulary
Format
Data Access Request
Dataset pipeline status
Time to dataset access
Access request cost
Access method category
Access service description
Organisations and individuals wanting to use certain kinds of data need to show they meet strict data governance standards by completing the NHS Digital DARS application process.
The DARS team makes sure we only supply sensitive patient level data to organisations that look after it according to Information Governance (IG) requirements, and use it to improve health and care services.
Jurisdiction
Data use limitation
Data use requirements
Data Controller
University of Leeds Leeds Teaching Hospital Trust
Data Processor
University of Leeds Leeds Teaching Hospital Trust